DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New Engl J Med. 2020;383(7):617–29. https://doi.org/10.1056/NEJMoa2012971.
CAS Article PubMed Google Scholar
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. New Engl J Med. 2018;378(12):1107–20. https://doi.org/10.1056/NEJMoa1713976.
CAS Article PubMed Google Scholar
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45. https://doi.org/10.1182/blood.2020004856.
CAS Article PubMed PubMed Central Google Scholar
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. New Engl J Med. 2019;380(23):2225–36. https://doi.org/10.1056/NEJMoa1815281.
CAS Article PubMed Google Scholar
Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–87. https://doi.org/10.1182/blood.2020008727.
CAS Article PubMed Google Scholar
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623–9. https://doi.org/10.1002/ajh.25796.
CAS Article PubMed Google Scholar
Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118(14):3901–10. https://doi.org/10.1182/blood-2010-11-317438.
CAS Article PubMed Google Scholar
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130(22):2401–9. https://doi.org/10.1182/blood-2017-06-788786.
CAS Article PubMed Google Scholar
Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–42. https://doi.org/10.1016/s1470-2045(20)30525-8.
CAS Article PubMed Google Scholar
Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210–2. https://doi.org/10.1038/leu.2013.216.
CAS Article PubMed Google Scholar
Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15(5):1132–44. https://doi.org/10.1158/1535-7163.Mct-15-0730.
CAS Article PubMed Google Scholar
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10(1):69. https://doi.org/10.1186/s13045-017-0439-6.
CAS Article PubMed PubMed Central Google Scholar
Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(8):1766–71. https://doi.org/10.1093/annonc/mdv237.
He J, Chen Q, Gu H, Chen J, Zhang E, Guo X, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018;103(8):1369–79. https://doi.org/10.3324/haematol.2017.181172.
CAS Article PubMed PubMed Central Google Scholar
Lin L, Que Y, Lu P, Li H, Xiao M, Zhu X, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway. Front Pharmacol. 2020;11:569651. https://doi.org/10.3389/fphar.2020.569651.
CAS Article PubMed PubMed Central Google Scholar
San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers. 2019. https://doi.org/10.3390/cancers11111794.
Article PubMed PubMed Central Google Scholar
Touzeau C, Maciag P, Amiot M, Moreau P. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32(9):1899–907. https://doi.org/10.1038/s41375-018-0223-9.
CAS Article PubMed Google Scholar
Inoue S, Walewska R, Dyer MJ, Cohen GM. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia. 2008;22(4):819–25. https://doi.org/10.1038/leu.2008.1.
CAS Article PubMed Google Scholar
Adams CM, Hiebert SW, Eischen CM. Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies. Cancer Res. 2016;76(3):736–48. https://doi.org/10.1158/0008-5472.Can-15-1751.
CAS Article PubMed Google Scholar
Locatelli SL, Cleris L, Stirparo GG, Tartari S, Saba E, Pierdominici M, et al. BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia. 2014;28(9):1861–71. https://doi.org/10.1038/leu.2014.81.
CAS Article PubMed Google Scholar
Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1–17. https://doi.org/10.1080/10428194.2017.1283032.
CAS Article PubMed Google Scholar
Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11(11):941–941. https://doi.org/10.1038/s41419-020-03144-y.
CAS Article PubMed PubMed Central Google Scholar
Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, et al. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother. 2014;68(4):483–91. https://doi.org/10.1016/j.biopha.2014.03.011.
CAS Article PubMed Google Scholar
Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 2017;9:83. https://doi.org/10.1186/s13148-017-0377-8.
CAS Article PubMed PubMed Central Google Scholar
Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, et al. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair. Clin Epigenetics. 2019;11(1):137. https://doi.org/10.1186/s13148-019-0723-0.
CAS Article PubMed PubMed Central Google Scholar
Tsukuda T, Fleming AB, Nickoloff JA, Osley MA. Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae. Nature. 2005;438(7066):379–83. https://doi.org/10.1038/nature04148.
CAS Article PubMed PubMed Central Google Scholar
Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28(5):739–45. https://doi.org/10.1016/j.molcel.2007.11.015.
CAS Article PubMed Google Scholar
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002;100(1):194–9. https://doi.org/10.1182/blood.v100.1.194.
CAS Article PubMed Google Scholar
Wuillème-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005;19(7):1248–52. https://doi.org/10.1038/sj.leu.2403784.
CAS Article PubMed Google Scholar
Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, et al. Distribution of bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood. 2011;118(5):1329–39. https://doi.org/10.1182/blood-2011-01-327197.
CAS Article PubMed PubMed Central Google Scholar
Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci CMLS. 2014;71(20):3885–901. https://doi.org/10.1007/s00018-014-1656-6.
CAS Article PubMed Google Scholar
Natarajan U, Venkatesan T, Radhakrishnan V, Samuel S, Rasappan P, Rathinavelu A. Cell cycle arrest and cytotoxic effects of SAHA and RG7388 mediated through p21(WAF1/CIP1) and p27(KIP1) in cancer cells. Medicina (Kaunas, Lithuania). 2019. https://doi.org/10.3390/medicina55020030.
Jingsong H, Qingxiao C, Huiyao G, Jing C, Enfan Z, Xing G, et al. Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease. Haematologica. 2018;103(8):1369–79. https://doi.org/10.3324/haematol.2017.181172.
Pack LR, Daigh LH, Chung M, Meyer T. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2. N
留言 (0)